Eli Lilly and Company operates in the healthcare sector, specifically within the drug manufacturing industry. As of September 8, 2025, the company has a market capitalization of approximately $651.91 billion. The fundamentals indicate a trailing P/E ratio of 47.62 and a forward P/E of 24.1, suggesting a premium valuation relative to earnings. The price-to-sales ratio stands at 12.24, and the price-to-book ratio is notably high at 35.68, reflecting investor expectations for future growth. Eli Lilly's return on equity is robust at 86.3%, with a profit margin of 25.9% and an operating margin of 45.8%. Revenue for the trailing twelve months is reported at $53.26 billion, with a year-over-year revenue growth of 37.6%. In terms of ownership, institutional investors hold a significant 83.87% of the company, while insiders own 16.4%. This high level of institutional ownership may indicate confidence in the company's prospects. From a technical perspective, Eli Lilly's stock closed at $727.30, with a recent decline of 2.11% for the day and a slight decrease of 0.65% over the past week. The stock is currently near its 52-week high, but it is trading below both its 50-day and 200-day